Off-label prescribing in the treatment of dermatologic disease

Journal of the American Academy of Dermatology

Volumn 47, Issue 2, 2002, Pages 217-223

  Sugarman, Joel H ^a   Fleischer Jr, Alan B ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMMONIUM LACTATE; ANTI ACNE AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACITRACIN; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; DERMATOLOGICAL AGENT; DIFLORASONE DIACETATE; DIPHENHYDRAMINE; ERYTHROMYCIN; FLUOCINONIDE; FLUOROURACIL; HYDROCORTISONE; KETOCONAZOLE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; METRONIDAZOLE; MINOCYCLINE; NEOSPORIN; POLYSPORIN; PREDNISONE; PSEUDOMONIC ACID; RETINOIC ACID; STEROID; TETRACYCLINE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ACNE; ACTINIC KERATOSIS; ARTICLE; ATOPIC DERMATITIS; CLINICAL PRACTICE; CONTACT DERMATITIS; ECZEMA; HERPES ZOSTER; HUMAN; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; ROSACEA; SEBORRHEIC DERMATITIS; SKIN DISEASE; VERRUCA VULGARIS; VIRUS INFECTION;

EID: 0036696323     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120469     Document Type: Article

References (19)

1. Christopher WL. "Off-label" drug prescriptions: filling the regulatory vacuum. Food Drug Law J 1993;48:247-8.
2. Brosgart CC, Mitchell T, Charlebois E, Coleman R, Mehalko S, Young J, et al. Off-label drug use in human immunodeficiency virus disease. J AIDS Hum Retrovirol 1996;12:S6-62.
3. Li VW, Jaffe MP, Li WW, Haynes HA. "Off-label" dermatologic therapies: usage, risks, and mechanisms. Arch Dermatol 1998; 134:1449-54.
4. Lipman MM. Using approved drugs for unapproved purposes. Consumer Reports on Health 1998;Feb:10.
5. Stoffelmayr KJ. Products liability and "off-label" uses of prescription drugs. Univ Chicago Law Rev 1996;63:275-7.
6. Henry V. "Off-label" prescribing: legal implications. J Legal Med 1999;20:365-83.
7. Tenney JB, White KL, Williamson JW. National Ambulatory Medical Care Survey: background and methodology. Washington (DC): National Center for Health Statistics. Vital and Health Statistics; 1974. p. 2.
8. Feldman SR, Fleischer AB, Williford PM, White R, Byington R. Increasing utilization of dermatologists by managed care: an analysis of the National Ambulatory Medical Care Survey, 1990-1994. J Am Acad Dermatol 1997;37:184-8.
9. International Classification of Disease Coding Manual. ICD-9-CM. 1990-1997.
10. Feldman SR, Fleischer AB, Young AC, Williford PM. Time-efficiency of nondermatologists compared with dermatologists in the treatment of skin disease. J Am Acad Dermatol 1999;40: 194-9.
11. Physicians desk reference. Montvale (NJ): Medical Economics; 1999.
12. United States Pharmacopeia dispensing information. Taunton MA): Micromedex, Inc; 1999.
13. National Association of Chain Drug Stores. "Off-label" drug useunapproved uses for approved drugs. Chain Pharmacist Practice Memo 1997;1(11):4.
14. Is the FDA protecting consumers from dangerous "off-label" uses of medical drugs and devices? HR Report No. 102-1064 (1992). Reprinted in Congressional Record D31-01.
15. Rayburn WF, Farmer KC. "Off-label" prescribing during pregnancy. Obstet Gynecol Clin North Am 1997;24:471-3.
16. Cardwell MS. Preventing perinatal early-onset group B streptococcal infections. The new standard of care. J Legal Med 1997; 18:511-9.
17. Popovsky JL, Camisa C. New and emerging therapies for diseases of the oral cavity. Dermatol Clin 2000;18:113-25.
18. Conlan MF. Unapproved uses prove worrisome. Drug Topics 1996;(Oct 21):60.
19. FDA Modernization Act of 1997. FDA Backrounder (Nov 21, 1997). Available from: URL:http:/www.fda.gov.